Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GNI Group ( (JP:2160) ) has issued an update.
GNI Group reported FY2025 consolidated revenue of ¥26.84 billion, up 13.7% year on year, but swung to an operating loss of ¥3.48 billion and a loss attributable to owners of the parent of ¥4.41 billion, reversing the prior year’s profit. Despite the loss, total assets rose to ¥83.79 billion and equity attributable to owners increased to ¥50.15 billion, reflecting strengthened capital, while the company again withheld dividends and refrained from issuing an FY2026 earnings forecast due to difficulty in reasonably estimating performance in its pharmaceutical and drug discovery businesses.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. is a Japan-listed biopharmaceutical company focused on pharmaceuticals and drug discovery, operating under International Financial Reporting Standards and serving global healthcare markets. The company is led by President and CEO Ying Luo and is listed on the Tokyo Stock Exchange under code 2160, with activities spanning multiple pharma-related segments.
Average Trading Volume: 1,371,545
Technical Sentiment Signal: Buy
Current Market Cap: Yen143.2B
See more insights into 2160 stock on TipRanks’ Stock Analysis page.